Avastin

Fuzuloparib, both alone and combined with apatinib, improved patients' progression-free survival versus standard chemotherapy. 

Data from retrospective RNA profiling of more than 900 patients challenges prior studies suggesting high HER2 expression as an EGFR inhibitor resistance marker.

After reviewing evidence on the regimen from clinical trials and within a managed access program, the institute is recommending it for routine use in the NHS.